Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Jun 7, 2017
Distillery Therapeutics

Cancer

BioCentury | Mar 2, 2015
Clinical News

Sylvant siltuximab regulatory update

BioCentury | Jun 9, 2014
Clinical News

Sylvant siltuximab regulatory update

BioCentury | Apr 28, 2014
Clinical News

Sylvant siltuximab regulatory update

BioCentury | Mar 24, 2014
Clinical News

Sylvant siltuximab regulatory update

BioCentury | Dec 16, 2013
Clinical News

Siltuximab: Phase II data

BioCentury | Sep 9, 2013
Clinical News

Siltuximab regulatory update

BioCentury | Sep 4, 2013
Company News

J&J submits U.S., EU applications for siltuximab

BioCentury | Mar 5, 2012
Emerging Company Profile

OncoPep: Smoldering solution

OncoPep developing multi-peptide vaccine for smoldering multiple myeloma
Items per page:
1 - 10 of 17